HUMA News and Press, Humacyte Inc. From 11/20/23

2023-11-20 19:28:16 ET Summary Humacyte is a developer of implantable regenerative human tissue for trauma and other uses. Their core technology, Human Acellular Vessel, has shown higher rates of patency, lower amputation rates, and lower infection rates compared to synthetic graf...

– Presentations included results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under a humanitarian aid program to treat wartime injuries in Ukraine – – Results showed the HAV had higher rates of patency, and lower rates of amputation and i...

2023-11-15 17:30:35 ET Gainers Veeco Instruments  ( VECO ) +5% . Humacyte ( HUMA ) +5% . Expensify ( EXFY ) +5% . ContextLogic ( WISH ) +4% . Tetra Tech ( TTEK ) +4% . Losers: Cisco Systems ( CSCO ) -11% . ...

2023-11-10 00:21:02 ET Humacyte, Inc. (HUMA) Q3 2023 Earnings Conference Call November 09, 2023, 04:30 PM ET Company Participants Lauren Marek - Investor Relations, LifeSci Advisors Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financ...

2023-11-09 17:10:23 ET More on Humacyte Humacyte: Major Catalysts Ahead, Solid Prospects, Low Prices Humacyte Inc. (HUMA) Q2 2023 Earnings Call Transcript Biggest stock movers today: Rocket Lab USA, Riot Platforms, WestRock, Oracle and more Humacyte gains as ...

– Positive top line results from the V005 Phase 2/3 trial of the Human Acellular Vessel™ (HAV™) in vascular trauma repair – – BLA for an indication in vascular trauma planned to be filed with the FDA during the current quarter – - ...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Humacyte Inc. (HUMA) is expected to report $-0.25 for Q3 2023

2023-11-08 17:35:57 ET More on Humacyte Humacyte: Major Catalysts Ahead, Solid Prospects, Low Price Biggest stock movers today: Rocket Lab USA, Riot Platforms, WestRock, Oracle and more Seeking Alpha’s Quant Rating on Humacyte For further details see: ...

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the third quarter ended September 30, 2023, on ...